A review of pluronic lecithin organogel as a topical and transdermal drug delivery system

Hospital Pharmacist

Volumn 12, Issue 7, 2005, Pages 267-270

  Murdan, Sudaxshina ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DEXAMETHASONE; DICLOFENAC; DILTIAZEM; ESTRADIOL; ESTRIOL; FLUOXETINE; HALOPERIDOL; ISOPHANE INSULIN; KETOPROFEN; LEVODOPA; LIDOCAINE; MORPHINE; NEUROLEPTIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHOSPHATIDYLCHOLINE; PIROXICAM; PLURONIC LECITHIN ORGANOGEL; PRASTERONE; PROCHLORPERAZINE; PROGESTERONE; SECRETIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; THIAMAZOLE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; LIPID SOLUBILITY; NONHUMAN; REVIEW; SKIN ABSORPTION; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 23044496790     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Goggins P. Topicals: Isn't it time for something novel? Proceedings of the United Kingdom and Ireland Controlled Release Society Annual Meeting; 2005 Jan 6; Birmingham. Loughborough: United Kingdom and Ireland Controlled Release Society; 2005.
2. Scartazzini R, Luisi PL. Organogels from lecithins. Journal of Physical Chemistry 1988;92:829-33.
3. The history of pluronic lecithin orgaogel: an interview with Marty Jones. International Journal of Pharmaceutical Compounding 2003;7:180-3.
4. Charoenbanpachon S, Krasieva T, Ebihara A, Osann K, Wilder-Smith P. Acceleration of ALA-induced PpIX fluorescence development in the oral mucosa. Lasers in Surgery and Medicine 2003;32:185-8.
5. Marek CL. Issues and opportunities: compounding for dentistry. International Journal of Pharmaceutical Compounding 1999;3:4-7.
6. Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: a review. The Journal of the American Dental Association 2000;131:184-95.
7. Franckum J, Ramsay D, Das NG, Das SK. Pluronic lecithin organogel for local delivery of anti-inflammatory drugs. International Journal of Pharmaceutical Compounding 2004;8:101-5.
8. Ketoprofen 2.5 per cent in pluronic lecithin organogel. International Journal of Pharmaceutical Compounding 1999;3:473.
9. Ketoprofen 10 per cent in pluronic lecithin organogel. International Journal of Pharmaceutical Compounding 2002;6:368.
10. Ketoprofen 10 per cent, cyclobenzaprine 1 per cent and lidocaine 5 per cent in pluronic lecithin organogel. International Journal of Pharmaceutical Compounding 1998;2:154.
11. Piroxicam 0.5 per cent in pluronic lecithin organogel. International Journal of Pharmaceutical Compounding 1999;3:133.
12. Selegiline hydrochloride 10 mg/mL in pluronic lecithin organogel. International Journal of Pharmaceutical Compounding 2004;8:59.
13. Schaller JL, Briggs B, Briggs, M. Progesterone organogel for premenstrual dysphoric disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000;39:546.
14. Bashford R, Horrigan JP. Progesterone organogel for premenstrual dysphoric disorder [comments]. Journal of the American Academy of Child and Adolescent Psychiatry 2000;39:546-7.
15. Shippen E. Progesterone organogel for premenstrual dysphoric disorder [letter]. Journal of the American Academy of Child and Adolescent I Psychiatry 2001;40:262.
16. Guy RH, Hadgraft J. Selection of drug candidates for transdermal drug delivery. In: J Hadgraft, R H Guy, editors. Transdermal drug delivery. Development issues and research initiatives. New York: Marcel Dekker, Inc; 1989. pp59-77.
17. Hoffmann G, Marks SL, Taboada J, Hosgood-Pagel G, Wofsheimer KL. Topical methimazole treatment in cats with hyperthyroidism. Journal of Feline Medicine and Surgery 2003;5:77-82.
18. Hoffman SB, Yoder AR, Trepanier LA. Bioavailability of transdermal methimazole in a pluronic lecithin organogel in healthy cats. Journal of Veterinary Pharmacology and Therapeutics 2002;25:189-93.
19. Ciribassi J, Luescher A, Pasloske KS, Robertson-Plouch C, Zimmerman A, Kaloostian-Whittymore L. Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. American Journal of Veterinary Research 2003;64:994-8.
20. Willis-Goulet HS, Schmidt BA, Nickiin CF, Marsella R, Kunkle GA, Tebbett IR. Comparison of serum dexamethasone concentrations in cats after oral or transdermal administration using pluronic lecithin organogel: a pilot study. Veterinary Dermatology 2003;14:83-9.
21. Mealey KL, Peck KE, Bennett BS, Sellon RK, Swinney GR, Melzer K, et al. Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats. Journal of Veterinary Internal Medicine 2004;18:43-6.
22. Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomised clinical trial in patients with osteoarthritis of the knee. The Journal of Rheumatology 1999;26:2659-63.
23. Burnham R, Gregg R, Healy P, Steadward R. The effectiveness of topical diclofenac for lateral epicondylitis. Clinical Journal of Sports Medicine 1998;8:78-81.
24. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. European Journal of Pharmacology 1998;354(Suppl):R13-14.
25. Williman H, Walde P, Luisi PL, Gazzaniga A, Stroppolo F. Lecithin organogel as matrix for transdermal transport of drugs. Journal of Pharmaceutical Sciences 1992;81:871-4.
26. Xenex Laboratories Inc.Transderma premium lecithin organogel base. Available at www.xenex. hcsn.com/Technical%20Information.ihtml (accessed 28 June 2005).